MiKasome

MiKasome®

Amikacin liposome Infectious disease An agent in clinical trials for treating complicated UTIs, acute infections in cystic fibrosis, nosocomial pneumonia
References in periodicals archive ?
In addition, the company recently initiated a large, randomized study in complicated UTI comparing different doses of MiKasome given as a single administration.
Nasdaq: NXTR) this weekend presented results from the second Phase I clinical study of the company's proprietary antibiotic MiKasome (a liposomal formulation of amikacin) at the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Preliminary Phase II data presented today show patients who received a one-day, single dose regimen with MiKasome (liposomal amikacin), produced by NeXstar Pharmaceuticals Inc.
hematological malignancies; and Phase I and II trials for MiKasome, a
Clinical trials currently under way at NeXstar Pharmaceuticals include Phase III trials for AmBisome in additional indications; Phase I and II trials for MiKasome, a liposomal formulation of the antibiotic amikacin; and additional Phase I and II trials for DaunoXome, a liposomal formulation of the anticancer drug daunorubicin, which is currently indicated for the treatment of Kaposi's sarcoma, with the goal of obtaining other indications, particularly in hematological malignancies.
Nasdaq/NMS:NXTR) today announced that new Phase II data for its proprietary investigational antibiotic MiKasome (liposomal amikacin) has been accepted for presentation on Monday, March 22, 1999, at the 9th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in Berlin, Germany.
Nasdaq: NXTR) announced today the initiation of its third Phase II clinical trial for MiKasome, the company's proprietary liposomal formulation of the antibiotic amikacin.
Highlights of early-stage animal studies conducted by NeXstar Pharmaceuticals indicate that MiKasome demonstrated the following properties:
Nasdaq: NXTR) today reported that it is initiating the second arm of an ongoing Phase II clinical trial of MiKasome, the company's liposomal formulation of amikacin, in the treatment of complicated urinary tract infections (UTIs).
The company said this increase was due to expanded clinical trial activity for both DaunoXome (daunorubicin citrate liposome injection) and MiKasome (amikacin liposome injection); for additional pre-clinical spending on aptamer drug candidates from the SELEX process, the company's proprietary combinatorial chemistry technology; and the above-mentioned AmBisome development expenses.
Based on our extensive preclinical data and our initial phase I results that to date confirm our preclinical findings, we believe that MiKasome will become a very important drug to the company.